29681-46-7

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 5-METHOXY-3-PYRIDINECARBOXYLATE, 90% is used as an intermediate in the synthesis of various drugs for its antimicrobial and antioxidant properties. It contributes to the development of medications that require these characteristics to enhance their efficacy and safety.
Used in Agrochemical Industry:
In the agrochemical industry, METHYL 5-METHOXY-3-PYRIDINECARBOXYLATE, 90% is utilized as an intermediate in the production of agricultural chemicals. Its antimicrobial properties make it suitable for creating products that protect crops from diseases, while its antioxidant properties can help in preserving the quality and shelf life of these agrochemicals.

InChI:InChI=1/C8H9NO3/c1-11-7-3-6(4-9-5-7)8(10)12-2/h3-5H,1-2H3

Upstream product

• 186581-53-3 diazomethane 
• 30766-22-4 methyl 5-hydroxy-3-pyridinecarboxylate 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 29681-44-5 5-bromo-3-pyridine carboxylic acid methyl ester 
• 107-31-3 Methyl formate 
• 74-88-4 methyl iodide 
• 850991-69-4 5-methoxy-3-pyridinylboronic acid 
• 3186-53-6 O-methyl S-p-methylphenyl thiocarbonate 
• 20826-03-3 5-methoxypyridine-3-carboxylic acid 
• 109345-94-0 3-hydroxy-5-methoxypyridine 
• 138-24-9 phenyltrimethylammonium chloride 

Downstream Products

• 20826-03-3 5-methoxypyridine-3-carboxylic acid 
• 1374353-52-2 1-(2-fluoro-6-methoxybenzyl)-5-methoxypiperidine-3-carboxylic acid 
• 1374353-50-0 methyl 1-(2-fluoro-6-methoxybenzyl)-5-methoxypiperidine-3-carboxylate 
• 1355730-03-8 methyl 2-(difluoromethyl)-5-methoxynicotinate 
• 1355729-95-1 methyl 4-(difluoromethyl)-5-methoxynicotinate 
• 1355729-44-0 methyl 6-(difluoromethyl)-5-methoxynicotinate 
• 937202-11-4 (5-methoxypyridin-3-yl)methanol 
• 177661-64-2 3-methoxy-5-[1-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-1H-imidazol-2-yl]pyridine 
• 298204-74-7 5-(methyloxy)pyridine-3-carbonitrile 

Relevant academic research and scientific papers

A predictive model for additions to: N -alkyl pyridiniums

Disclosed in this communication is a thorough study on the dearomative addition of organomagnesium nucleophiles to N-alkyl pyridinium electrophiles. The regiochemical outcomes have observable and predictable trends associated with the substituent patterns on the pyridinium electrophile. Often, the substituent effects can be either additive, giving high selectivities, or ablative, giving competing outcomes. Additionally, the nature of the organometallic nucleophilic component was also investigated for its role in the regioselective outcome. The effects of either reactive component are important to both the overall reactivity and site of nucleophilic addition. The utility of these observed trends is demonstrated in a concise, dearomative synthesis of a tricyclic compound shown to have insecticidal activity. This journal is

Palladium-Catalyzed, Copper(I)-Promoted Methoxycarbonylation of Arylboronic Acids with O-Methyl S-Aryl Thiocarbonates

Here, we report O-methyl S-aryl thiocarbonates as a versatile esterification reagent for palladium-catalyzed methoxycarbonylation of arylboronic acid in the presence of copper(I) thiophene-2-carboxylate (CuTC). The reaction condition is mild, and a variety of substituents including sensitive-Cl,-Br, and free-NH2 could be tolerated. Further applications in the late-stage esterification of some pharmaceutical drugs demonstrate the broad utility of this method.

Nickel-catalyzed carboxylation of aryl and heteroaryl fluorosulfates using carbon dioxide

The development of efficient and practical methods to construct carboxylic acids using CO2 as a C1 synthon is of great importance. Nickel-catalyzed carboxylation of aryl fluorosulfates and heteroaryl fluorosulfates with CO2 is described, affording arene carboxylic acids with good to excellent yields under mild conditions. In addition, a one-pot phenol fluorosulfation/carboxylation is developed.

TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS

A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS

The present invention is directed to morpholine carboxamide compounds which are antagonists of prokineticin receptors, in particular antagonists of prokineticin 2 receptors, and which are useful in the treatment or prevention of neurological and psychiatr

3-(2-Aminoethyl)pyridine analogs as α4β2 nicotinic cholinergic receptor ligands

An examination of several 3-(2-aminoethyl)pyridine analogs suggests that they likely orient at α4β2 nicotinic cholinergic receptors in a different fashion than their correspondingly substituted nicotine analogs.

PYRROLOPYRIDAZINE DERIVATIVES

The invention relates to compound of the formula (I) or its salt, in which R1, R2, R3 and R4 are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-α mediated diseases.

Selective cyclooxygenase-2 inhibitors: Heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents

A series of heteroaryl modified 1,2-diarylimidazoles has been synthesized and found to be potent and highly selective (1000-9000-fold) inhibitors of the human COX-2.3-Pyridyl derived COX-2 selective inhibitor (25) exhibited excellent activity in acute (carrageenan induced paw edema, ED50 = 5.4 mg/kg) and chronic (adjuvant induced arthritis, ED50 = 0.25 mg/kg) models of inflammation. The relatively long half-life of 25 in rat and dog prompted investigation of the pyridyl and other heteroaromatic systems containing potential metabolic functionalities. A number of substituted pyridyl and thiazole containing compounds (e.g., 44, 46, 54, 76, and 78) demonstrated excellent oral activity in every efficacy model evaluated. Several orally active diarylimidazoles exhibited desirable pharmacokinetics profiles and showed no GI toxicity in the rat up to 100 mg/kg in both acute and chronic models. The paper describes facile and practical syntheses of the targeted diarylimidazoles. The structure-activity relationships and antiinflammatory properties of a series of diarylimidazoles are discussed.